DTC Eligibility for OTCQX Trading in the U.S.

Investing News NetworkYour trusted source for investing success

Download our investor reports
Start Here GuidesOutlook Reports
Copyright 2023 © Dig Media Inc.

Your trusted source for investing success since 2007. Renowned for our market outlook reports and investing guides.

clr 131

LATEST ARTICLES
Biotech Investing

FDA Grants Rare Pediatric Disease Designation to Cellectar Biosciences’ CLR 131 for the Treatment of Osteosarcoma

Pharmaceutical Investing

Cellectar Granted U.S. Patent for the Treatment of Various Cancers and Cancer Stem Cells with CLR 131

Pharmaceutical Investing

Cellectar Granted Orphan Drug Designation for CLR 131 to Treat Rhabdomyosarcoma

Pharmaceutical Investing

Cellectar Granted Seminal U.S. Patent for Phospholipid-Ether Analogs as Cancer-Targeting Drug Vehicles

Biotech Investing

Cellectar Reports 2017 Financial Results and Provides a Corporate Update

Pharmaceutical Investing

Cellectar Biosciences Granted Orphan Drug Designation for CLR 131 to Treat Neuroblastoma

Biotech Investing

Cellectar Receives USPTO Notice of Allowance for Patent Covering Use of CLR 131 in Multiple Myeloma

Pharmaceutical Investing

Cellectar Initiates DLBCL Cohort in Phase 2 Trial of CLR 131

Pharmaceutical Investing

Cellectar Biosciences Shares CLR 131 Trial Data

Pharmaceutical Investing

Cellectar Biosciences Presents New Preclinical Data

Pharmaceutical Investing

Cellectar Biosciences Obtains Additional Patents

MARKETS

Markets
TSX20024.63+352.38
TSXV609.08+3.07
DOW33762.76+701.19
S&P 5004282.37+61.35
NASD13240.77+139.78
ASX7145.10+34.30

COMMODITIES

Commodities
Gold1948.19+0.20
Silver23.62+0.01
Copper3.73+0.02
Palladium1713.170.00
Platinum1087.260.00
Oil71.870.00
Heating Oil2.360.00
Natural Gas2.18+0.02

DOWNLOAD FREE REPORTS

BROWSE COMPANIES BY SECTOR

loader